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Ovarian cancer (OC) is the leading cause of death from gynaecological malignancies in the UK. Despite 22 
considerable funding to develop new treatments, 10-year survival remains poor at ~30%. This 23 
translates into 4,271 deaths annually in the UK, 42,700 in Europe and 152,000 deaths annually 24 
worldwide. High (e.g.-BRCA1/BRCA2) and moderate (e.g.-RAD51C/RAD51D/BRIP1) penetrance gene-25 
mutations account for most of the known hereditary-risk of OC. At least 10% of women with epithelial-26 
OC carry these germline mutations. BRCA1/BRCA2 carriers have a 17%-44% risk of OC and 65-72% risk 27 
of breast cancer (BC), while RAD51C/RAD51D/BRIP1 carriers have a 6-11% risk of OC. Primary surgical 28 
prevention in the form of risk-reducing salpingo-oophorectomy (RRSO) remains the most effective 29 
option and gold-standard for OC-risk reduction, particularly given the lack of an effective national OC-30 
screening programme. The role of RRSO for primary surgical prevention has expanded to include not 31 
just BRCA1/BRCA2 carriers but also women at intermediate-risk (>4-5% lifetime-risk of OC). RRSO 32 
reduces OC-risk by 80-96%. Whilst initial data suggested pre-menopausal RRSO reduced BC-risk by 33 
half, more recent publications have questioned this.1 Nevertheless, RRSO reduces all-cause (HR=0.40, 34 
95%CI:0.26-0.61), BC-specific (HR=0.44, 95%CI:0.26-0.76), and OC-specific (HR=0.25, 95%CI:0.08-0.75) 35 
mortality.2 36 
Limitations of premenopausal RRSO:  37 
Premenopausal RRSO leads to premature surgical menopause which has detrimental long-term health 38 
consequences. It is associated with an increased risk of heart-disease, stroke, osteoporosis, vasomotor 39 
symptoms, mood changes, sleep disturbance, reduced libido, vaginal dryness, sexual-dysfunction and 40 
neurocognitive decline, especially if unable to use hormone-replacement-therapy (HRT). A 3.03% 41 
absolute increased-risk of cardiovascular mortality has been reported with premenopausal 42 
oophorectomy without HRT (NNH=1:33).  BRCA-carriers who have estrogen-receptor positive BC 43 
cannot take HRT. Additionally, vasomotor symptoms and sexual-dysfunction are not fully alleviated 44 
by HRT, with symptom levels remaining above those who retain their ovaries. Consequently many 45 
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women choose to delay RRSO until after menopause. Furthermore, RRSO has a 1.5-5% complication 46 
rate.  47 
Role of fallopian-tube in etiopathogenesis of OC 48 
Following initial observations in BRCA-mutation carriers,3 there is now broad acceptance of the role 49 
of the fallopian-tube in the etiopathogenesis of epithelial-OC. Genotoxic injury leads to p53-mutations 50 
and loss of p53-function (represented by p53-signatures) in the distal fallopian-tube. High-grade 51 
serous ovarian cancers (HGSOC) may develop through further DNA damage from the combined 52 
functional loss of p53 and BRCA (or related pathways) or through epigenetic reprogramming. A 53 
precursor lesion called serous-tubal-intraepithelial-carcinoma (STIC) has been defined which is 54 
present as a continuum with early tubal carcinomas, supporting transition from one to another. STICs 55 
have been reported in up to 60% of sporadic HGSOC as well and in 92% of cases have identical TP53 56 
gene-mutations to concurrent pelvic serous carcinomas. Molecular profiling supports the common 57 
origin of STICs/HGSC from the distal tube. Occult STIC/invasive tubal cancers occur in 5-8% of RRSO 58 
specimens from BRCA-mutation carriers. Around 70% of these lesions were found in the distal-tube 59 
and not the ovary. 60 
Risk-reducing early-salpingectomy and delayed oophorectomy (RRESDO) 61 
The acceptance of a central role for the tube in OC etiopathogenesis coupled with the detrimental 62 
health sequelae of premature menopause, has led to the attractive proposal of a two-step alternative 63 
OC surgical prevention strategy in pre-menopausal women at increased (high/intermediate) OC-risk 64 
who have completed their family but decline or wish to delay RRSO. It involves early-salpingectomy 65 
(ES) as the first-step followed by delayed-oophorectomy (DO) after menopause. RRESDO has the 66 
advantage of providing a level of risk reduction whilst conserving ovarian function and avoiding 67 
negative side-effects/health-consequences of premature menopause. We reviewed the literature for 68 
ES and DO for OC prevention. Appendix-S1 describes the search strategy and Figure-S1 the flow-chart 69 
of results. Searches were performed in MEDLINE, EMBASE, Pubmed, CINAHL, PsychINFO and clinical-70 
4 
 
trial registries (ISRCTN, clinicaltrials.gov). Table-1 lists the current studies reporting outcomes of 71 
RRESDO.4-11 The quality of studies were assessed using the MINORS (Methodological Index for Non-72 
Randomized Studies) checklist and CASP (Critical Appraisal Skills Programme) qualitative-research 73 
checklist. 74 
Acceptability 75 
Data on putative acceptability of RRESDO amongst women at high-risk of OC are limited to one small 76 
questionnaire study and one qualitative study in BRCA1/BRCA2 carriers.4, 8 Interest in RRESDO has 77 
been reported in 34% of women in a US survey (n=204)8 and 44% in a Dutch qualitative study (n=39).4  78 
35%-44% women were reported as being unsure about RRESDO and 12%-30% as disinterested.4, 8 A 79 
recent non-randomised, prospective cohort, pilot study (n=43) with three study arms (RRESDO, RRSO, 80 
screening) found 28% uptake rate for RRESDO.11  There are no data on acceptability of RRESDO in 81 
intermediate OC-risk women eligible for surgical prevention. A multicentre, prospective, UK study is 82 
evaluating views of high and intermediate-risk women (ISRCTN12310993). A UK-study found 60% of 83 
gynaecological oncologists and geneticists favoured offering RRESDO to pre-menopausal high-risk 84 
women declining RRSO, along-with strong support for a clinical-trial and creation of a UK-wide registry 85 
with ~80% favouring these options.5 A Dutch qualitative-study also found high acceptability amongst 86 
health professionals for a clinical-trial.4  87 
Benefits/facilitators and barriers/risks: RRESDO 88 
The main reason for undergoing RRESDO reported by women at high OC-risk and health professionals 89 
is the ability to obtain some OC-risk reduction whilst avoiding detrimental consequences of early 90 
menopause.4, 5, 8 Barriers to participation for patients included surgical complications, potential 91 
ovarian damage, family-history, previous BC, surgical costs, seriousness of OC and uncertainty on level 92 
of benefit obtained from early salpingectomy (ES) and poor pre-operative counselling of negative side-93 
effects of RRSO.4 Barriers perceived by health-professionals included need for two operations, lack of 94 
precision of OC-risk reduction, ease of decision to undergo RRSO, health-care costs, potential loss of 95 
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reduction in BC-risk, need for long-term follow-up with possible attrition from DO. Interestingly 96 
potential lack of BC-risk reduction was not raised by patients4 and this in itself has become uncertain 97 
with recent reports finding no benefit of reduction in BC from RRSO. Although RRESDO involves two 98 
surgical procedures, preliminary evidence indicates that most women would find two procedures 99 
acceptable.8, 11  100 
Other Outcomes 101 
Preliminary pilot-data from a small study of 43 BRCA-mutation carriers suggests, RRESDO and RRSO 102 
are both associated with decreased cancer worry and RRESDO is associated with reduced anxiety at 103 
12-months follow-up.11 One study suggests that RRESDO may be cost-effective compared to RRSO for 104 
a base-case with a utility-score for RRSO=0.82 and for ES=0.99, level of OC-risk reduction=60% and no 105 
attrition from DO. However, more recent data reports a RRSO utility-score of 0.95, the actual disutility 106 
for ES is unknown, the precise level of OC-risk reduction is unknown, and potential attrition from DO 107 
is missing, which together maintain uncertainty around the comparative cost-effectiveness of 108 
RRESDO.  109 
RRESDO should only be offered in a Clinical Trial/Research Study 110 
Lack of clarity on several key issues strengthens the case to currently offer RRESDO within a research 111 
setting.  The extent of OC-risk reduction and long-term health outcomes with ES remain unclear. While 112 
two retrospective population studies found a 35–42% reduction in OC-risk with salpingectomy in low-113 
risk women, these studies were limited by: indication and detection bias, wide confidence-intervals, 114 
small number of OC cases in salpingectomy subgroups and lack of adjustment for contraceptive pill 115 
use. Besides results from the low-risk population cannot be directly extrapolated to high-risk women. 116 
Salpingectomy will not prevent OC arising outside the tube or within tubal epithelium lined inclusion 117 
cysts. Residual fimbrial tissue implants may remain on the ovarian surface after salpingectomy in 10% 118 
of cases,12 and could become a potential site for malignant transformation. OC etiopathogenesis is 119 
complex and our current understanding of this is incomplete. There are different types of STIC and the 120 
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natural history, progression rates, outcomes and rate-limiting step in development of OC associated 121 
with each type is unknown. Moreover, STICs may not be precursors to all HGSOC cases.  The long-term 122 
impact of salpingectomy on ovarian function and premature menopause is unknown. Although short-123 
term data show no detrimental outcome for hormonal levels, blood-flow indices or surgical risks, 124 
these correlate more with fertility outcomes, and are not predictive of menopause. No validated 125 
hormonal criteria predicting duration of menopausal transition or time of final menstruation exist and 126 
only long-term assessments of hormonal levels/menstrual cycles can clarify this.  127 
Concerns exist amongst clinicians regarding attrition from DO. A proportion who do not undergo DO 128 
may develop OC. Uncertainties remain around the cost-effectiveness of RRESDO. There is need for 129 
standardisation of protocols for management and follow-up of (isolated) STIC lesions both at national 130 
and international levels. A suggested management protocol is given in Table-2, Supplementary Figure 131 
S2.  We reviewed the literature on management of STIC (Table-3) and found a limited evidence base. 132 
Isolated STIC was found in 2% (82/4,149) and occult invasive cancers in 2.2% (93/4,149) of women 133 
undergoing RRSO. We recommend bilateral salpingo-oophorectomy in isolated STIC with negative-134 
cytology but full staging in those with positive-cytology or an abnormal staging CT-scan. Implementing 135 
RRESDO within a research setting would also enable the development of a tissue-&-data bio-resource 136 
for translational research and secondary studies. 137 
Research studies offering RRESDO 138 
There are currently five important non-randomised trials investigating aspects of RRESDO being 139 
undertaken in France, the Netherlands, US and UK. (Table-4). Randomised studies for surgical 140 
prevention are not feasible or ethical in high-risk women. The ongoing studies vary with respect to 141 
primary outcomes, design and sample sizes. The French (Fimbriectomy) study is powered on OC/PPC 142 
incidence, while the others are powered on menopause-related quality-of-life (Dutch), DO uptake (US) 143 
and sexual function (UK, US). The French study does not involve DO.  DO is undertaken in the Dutch 144 
TUBA (TUbectomy with delayed oophorectomy to improve quality-of-life as alternative for risk-145 
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reducing salpingo-oophorectomy in BRCA1/2 mutation carriers) study at 40-45 years in BRCA1 and 45-146 
50 years in BRCA2 carriers; and in the US PSDO (Prophylactic-Salpingectomy-with-Delayed-147 
Oophorectomy) study three years after ES. DO is undertaken in premenopausal women well before 148 
onset of menopause in the US and Dutch studies. In the UK PROTECTOR (Preventing Ovarian Cancer 149 
through early Excision of Tubes and late Ovarian Removal) study DO is undertaken at menopause but 150 
offered earlier for those women who may choose to do so. Similarly, in the US WISP (Women Choosing 151 
Surgical Prevention Trial) study, women are given the choice as to when to undergo DO but are 152 
encouraged to have this done between 40-50 years. While the Dutch and the US PSDO-study only 153 
include BRCA-carriers, the French study also includes women ascertained using FH. The UK study 154 
includes high and intermediate risk women: BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 carriers and FH 155 
based assessment. The WISP-study in addition offers RRESDO to 156 
PALB2/BARD1/MSH2/MSH6/MLH1/PMS2/EPCAM mutation carriers. However mutations in the Lynch 157 
syndrome genes are predominantly associated with an increased risk of non-serous epithelial-OC.  In 158 
addition, there is insufficient evidence (lack of validated data) linking PALB2/BARD1/EPCAM/PMS2 159 
mutations with OC.  160 
Conclusion 161 
RRSO remains the gold-standard for surgical prevention in women at increased risk of OC. RRESDO is 162 
an alternative for women who have completed their family and prefer to decline or delay 163 
premenopausal RRSO. In the absence of long-term prospective outcome data, and unaddressed 164 
knowledge gaps highlighted above, RRESDO should only be offered within the controlled environment 165 
of a clinical-trial/research study. It is vital clinicians offer appropriate counselling on the advantages 166 
and limitations of salpingectomy versus standard RRSO for informed decision making and consent.  167 
Long-term follow-up is essential to minimise attrition from DO. As data from ongoing trials emerge it 168 
will help inform national and international guidelines on an early-salpingectomy and delayed-169 
oophorectomy strategy in women at increased risk of OC.   170 
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Table-1: Studies reporting RRESDO outcomes  
 
RRESDO – risk reducing early salpingectomy and delayed oophorectomy; OC – ovarian cancer; QoL – quality of life; RRSO – risk reducing salpingo-oophorectomy; RRES – risk reducing early 
salpingectomy 
¥Gynaecological oncologists; clinical geneticists; breast surveillance practitioners: medical oncologists, surgeons, medical doctors, nurses 
€Gynaecological oncologists; general obstetricians & gynaecologists; clinical geneticists; genetic counsellors 
#Members of the Korean Society of Gynecologic Oncology and attendants of the inaugural Hereditary Gynecologic Cancer Symposium in South Korea 
˜Quality of methodology assessed using the CASP (Critical Appraisal Skills Programme) qualitative research checklist 
*Quality of methodology assessed using the MINORS (Methodological Index for Non-Randomized Studies) checklist 
Publication Country Sample 
size (n) 
Study design Population Intervention Outcomes  Follow up  Quality of 
methodology 
Arts-de Jong, 
2015 
The Netherlands 62 Qualitative study BRCA1/BRCA2 mutation 
carriers; health 
professionals¥ 
Focus group interviews; 
semi-structured in-
depth interviews 
Putative acceptability, barriers and 
facilitators  
NA Good˜ 
Chandrasekaran, 
2015 
UK 173 Prospective cohort 
survey study 
Health professionals€ Online questionnaire Putative acceptability  NA 15/16* 
Choi, 2017 South Korea 54 Cross-sectional 
cohort study 
Health professionals# Online/paper 
questionnaire 
Putative acceptability  NA 14/16* 
Harmsen, 2015 
(study protocol) 
The Netherlands 510 Multicentre, 
prospective, cohort 
study 
BRCA1/BRCA2 mutation 
carriers, premenopausal, 
>25 years  
RRESDO 
RRSO 
Menopause specific QoL 15 years 21/24* 
Holman, 2014 US 204 Prospective cohort 
survey study 
BRCA1/BRCA2 mutation 
carriers 
Online questionnaire Putative acceptability  NA 15/16* 
Kwon, 2013 Canada 2,300 Markov Monte 
Carlo simulation 
model 
Hypothetical cohort of 
BRCA1/BRCA2 mutation 
carriers 
RRESDO 
RRES 
RRSO 
Incremental cost effectiveness 
ratio per quality adjusted life year  
NA NA 
Leblanc, 2011 
 
France 14 Single centre, 
prospective, cohort 
study 
BRCA1/BRCA2 mutation 
carriers 
Radical fimbriectomy Optimum surgical technique to minimise 
complications 
and ensure high 
quality specimens for histopathological 
examination 
Not 
reported 
13/16* 
Nebgen, 2018 US 43 Multicentre, 
prospective, cohort, 
pilot study 
BRCA1/BRCA2 mutation 
carriers, premenopausal, 
30-47 years 
RRESDO 
RRSO 
Screening 
Acceptability, surgical outcomes, QoL, 
cancer specific worry, anxiety, sexual 
function, body image  and menopausal 
symptoms  
12 
months 
22/24* 
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Table-2: Suggested management and follow up of STIC# lesions (without invasion) 
 
Histopathology 
and Cytology 
Management 
Staging CT 
Chest, 
abdomen, 
pelvis 
Surgical staging* 
Panel genetic testing** 
(BRCA1/BRCA2/RAD51C/
RAD51D/BRIP1) 
STIC with 
positive 
cytology 
   
STIC with 
negative 
cytology 
 
Not indicated unless 
abnormality on CT 
suggesting otherwise 
 
STIC with 
missing cytology  
Not indicated unless 
abnormality on CT 
suggesting otherwise 
 
 
#All cases of isolated STIC identified at salpingectomy alone (patients undergoing early salpingectomy) should have completion oophorectomy 
*Hysterectomy, omentectomy, pelvic/para-aortic lymphadenectomy (excision of all visible disease) 
**If not previously undertaken 
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Table-3: Studies reporting the management of STIC lesions in women at increased risk of ovarian cancer 
Publication Sample 
size (n) 
Median 
follow up in 
months 
(range) 
Isolated STIC Occult invasive 
cancers 
Staging for isolated STIC* Chemotherapy STIC recurrence 
Negative 
Cytology 
Positive 
cytology 
No 
cytology 
Negative 
Cytology 
Positive 
cytology 
No 
cytology 
Negative 
Cytology 
Positive 
cytology 
No 
cytology 
Negative 
Cytology 
Positive 
cytology 
No 
cytology 
Conner, 2014 385 60 (12-96) 6 2 0 17 3 1 0 3 0 0 1# 0 0 
Manchanda, 
2011 
308 Not 
reported 
6 3 0 5 0 3 0 0 0 0 0 0 0 
Powell, 2013 405 80 (40-150) 14 3 0 15 7 3 0 2 2 0 1~ 0 0 
Finch, 2006 159 Not 
reported 
1 0 0 6 0 0 0 0 0 0 0 0 0 
Carcangiu, 
2006 
50 26.5 (1-145) 2 0 1 3 0 0 0 0 0 0 0 0 0 
Lamb, 2006 113 29 3 1 0 3 3 1 0 1 1 0 0 0 0 
Medeiros, 
2006 
13 Not 
reported 
0 1 2 2 0 1 2 0 0 0 0 0 0 
Callahan, 
2007 
122 Not 
reported 
2 1 0 4 0 0 0 2 1 0 0 0 0 
Reitsma, 2013 360 60 (0-144) 3 0 0 4 0 0 0 0 0 0 0 0 0 
Wethington, 
2013 
593 28 (16–44) 11 1 0 0 6 1 0 0 0 0 0 0 0 
Sherman, 
2014 
966 Not 
reported 
4 0 0 21 0 0 0 0 0 0 0 0 0 
Zakhour, 2016 257 79 (20-138) 9 0 0 4 0 0 0 0 0 0 2£ 0 0 
Poon, 2016 138 79 (45-108) 1 1 1 2 0 0 0 0 0 0 0 0 0 
Hirst, 2009 45 Not 
reported 
0 0 1 4 0 0 0 0 0 0 0 0 0 
Van der 
Hoeven, 2018 
235 78 (59-96) 0 0 2 3 0 0 0 0 0 0 0 0 1$ 
Total (n) 4,149 - 62 13 7 93 19 10 2 8 4 0 4 0 1 
Total (%) - - 2.0 2.2 0.7 0.3 0.1 
*No upstaging reported in 31cases of isolated STIC identified at RRSO, where staging was undertaken 
#Recurrence 48 months after RRSO. No staging/chemotherapy after STIC confirmed. Presented with rising CA125 and ascites. 
~Recurrence 43 months after RRSO. No staging/chemotherapy after STIC confirmed. Presented with rising CA125 and omental deposits. 
£Recurrence 32 and 42 months after RRSO. No staging/chemotherapy after STIC confirmed. 
$Recurrence 36 months after RRSO. No staging/chemotherapy after STIC confirmed. 
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Timing of recurrence (range 32-48 months) of isolated STIC in the small number of reported cases is not that consistent with a missed metastases that would have necessarily have been identified at 
staging. One would have expected a missed metastases to present in 12-18 months without further treatment (given what we understand of OC progression through screening and tumour modelling 
studies), and not a delayed presentation at 3-4 years.  
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Table-4: Clinical trials investigating risk reducing salpingectomy as an alternative surgical strategy for ovarian cancer prevention in women at increased 
risk of ovarian cancer 
Study Country Study design Population Sample size Study arms Primary 
outcomes  
Secondary outcomes Follow up  Study 
Status 
PROTECTOR 
(ISRCTN25173360) 
 
UK Multicentre, 
prospective, 
cohort 
BRCA1/BRCA2/RAD51C/RAD51
D/BRIP1 mutation carriers  or 
FH of BC-&-OC or OC alone#, 
premenopausal, >30 years,  
1000 RRESDO 
RRSO 
Controls (no 
surgery) 
Sexual function Endocrine 
function/menopause; 
regret/satisfaction; surgical 
morbidity; QoL/psychological 
health; intraepithelial 
carcinomas; invasive cancers; 
utility scores for ES; cost-
effectiveness 
3 years  
(longer term follow up 
maintained through 
establishment of a 
national register) 
Recruiting 
TUBA 
(NCT02321228) 
Netherlands Multicentre, 
prospective, 
cohort 
BRCA1/BRCA2 mutation 
carriers, premenopausal, >25 
years  
510 RRESDO 
RRSO 
Menopause 
specific QoL 
QoL; sexual function; cancer 
worry; satisfaction/regret;  
surgical complications;  
intraepithelial carcinomas; 
invasive cancers; CVD risk 
factors; incidence of CVD; 
cost-effectiveness 
15 years Recruiting 
Radical 
Fimbriectomy* for 
Young BRCA Mutation 
Carriers 
(NCT01608074) 
France Multicentre, 
prospective, 
cohort 
BRCA1/BRCA2 mutation 
carriers  or high-risk FH, 
premenopausal, >35 years  
123 Radical 
fimbriectomy 
Number of 
OC/PPC 
occurring 
between 
fimbriectomy 
and menopause 
Morbidity; incidence of 
intraepithelial/invasive 
carcinomas at fimbriectomy; 
incidence and recurrence of 
BC; rate of DO 
15 years Closed to 
recruitment 
Prophylactic 
Salpingectomy With 
Delayed 
Oophorectomy 
(NCT01907789) 
US Multicentre, 
prospective, 
cohort 
BRCA1/BRCA2 mutation 
carriers, premenopausal, 30-47 
years  
80 RRESDO 
RRSO 
OC screening 
Proportion of 
participants 
undergoing DO 
after ES 
Acceptability; surgical 
outcomes; QoL; cancer 
specific worry; anxiety; sexual 
function; body image  and 
menopausal symptoms 
RRESDO arm 4 years; 
RRSO arm 1 year 
OC screening arm 3 
years (longer term 
follow up maintained 
through annual 
telephone follow up) 
 
Closed to 
recruitment 
WISP   
(NCT02760849) 
US Multicentre, 
prospective, 
cohort 
BRCA1/BRCA2/BRIP1/PALB2/R
AD51C/RAD51D/BARD1/MSH2/
MSH6/MLH1/PMS2/EPCAM 
mutation carriers, 
premenopausal, 30-50 years 
300 RRESDO (ISDO) 
RRSO 
Sexual function QoL 26 years Recruiting 
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PROTECTOR - Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal; TUBA - Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene 
Mutation Carriers; OC – ovarian cancer; BC – breast cancer; RRESDO – risk reducing early salpingectomy with delayed oophorectomy; RRSO – risk reducing salpingo-oophorectomy; QoL – 
quality of life; PPC – primary peritoneal cancer; ES – early salpingectomy; DO – delayed oophorectomy; FH – family history; CVD – cardiovascular disease; WISP - The Women Choosing 
Surgical Prevention Trial, ISDO – Interval Salpingectomy & Delayed Oophorectomy 
 
#Significant family history defined as:- BRCA negative: >2 individuals with ovarian cancer who are first degree relatives, >3 ovarian cancer case families; BRCA unknown: >2 ovarian cancer case 
families; Manchester Scoring System (MSS3) >15; BOADECIA/BRCAPRO combined BRCA1/BRCA2 probability >10% 
*Fimbriectomy involves removing the tube, fimbrio-ovarian junction and portion of ovary attached to fimbria (up to one-quarter of ovarian volume is removed). 
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Appendix-S1: Search strategy for literature search 
 
RRESDO – risk reducing early salpingectomy with delayed oophorectomy; RRSO – risk reducing early 
salpingectomy; OC - ovarian cancer 
 
 
Objective To identify published literature on RRESDO for surgical prevention of OC in women at 
increased risk.  
Data sources A systematic review of articles with the use of MEDLINE (1946 June 2018), EMBASE 
(1974 to June 2018), Pubmed (1996 to June 2018), CINAHL (1937 to June 2018), 
PsychINFO (1806 to June 2018) 
Search strategy 27 searches were undertaken 
1. (BRCA).ti,ab 
2. exp "BRCA"/ 
3. (BRCA AND "1 OR 2").ti,ab 
4. exp "BRCA AND 1 OR 2"/ 
5. (BRCA AND 1).ti,ab 
6. exp " BRCA AND 1"/ 
7. (BRCA AND 2).ti,ab 
8. exp "BRCA AND 2"/ 
9. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 
10. (SALPINGECTOMY).ti,ab 
11. exp "SALPINGECTOMY"/ 
12. (RISK REDUCING SALPINGECTOMY).ti,ab 
13. exp "RISK REDUCING SALPINGECTOMY"/ 
14. (EARLY SALPINGECTOMY).ti,ab 
15. exp "EARLY SALPINGECTOMY"/ 
16. 10 OR 11 OR 12 OR 13 OR 15  
17. (DELAYED OOPHORECTOMY).ti,ab 
18. exp "DELAYED OOPHORECTOMY"/ 
19. (DELAYED OVARIECTOMY).ti,ab 
20. exp "DELAYED OVARIECTOMY"/ 
21. 17 OR 18 OR 19 OR 20  
22. (OVARY CANCER).ti,ab 
23. exp "OVARY CANCER"/ 
24. (OVARIAN CARCINOMA).ti,ab 
25. exp "OVARIAN CARCINOMA"/ 
26. 22 OR 23 OR 24 OR 25  
27. 9 AND 16 AND 21 AND 26 
Eligibility criteria Women at increased risk of OC undergoing RRESDO; full articles in English language. 
Data extraction Citation and abstracts reviewed by author FG. Relevant papers reviewed by RM. 
Conclusion RRSO is the current gold standard for OC risk reduction but has limitations including 
premature menopause. RRESDO is a two staged surgical alternative for premenopausal 
women wanting to reduce their OC risk but at the same time avoid the detrimental 
health sequelae of premature menopause. There is a paucity of published data on 
outcomes of RRESDO. 
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Figure-S1: Flowchart of study selection 
 
 
27 records retrieved for review: 
MEDLINE = 1, EMBASE = 16, Pubmed = 8, 
CINAHL = 2, PsychINFO = 0). 
13 identified for title and abstract screening 
 
5 excluded for failure to meet eligibility 
criteria: 
1 abstract 
4 investigating salpingo-oophorectomy 
 
 
8 identified for full text screening 
 
8 included for qualitative synthesis (Table-1) 
 
14 duplicates excluded 
 
8 identified as relevant for data extraction 
 
